Status: Not yet recruiting
NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings
The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.
Participants needed: 450
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Duke UniversityUpdated: Jun 4, 2026Locations: 1
Eligibility criteria
Adults (age 18) at a participating carceral site; [+6]
Liver function test levels greater than four times normal (if we are unable to o... [+5]